26.50
+1.84(+7.46%)
Currency In USD
| Previous Close | 24.66 |
| Open | 25.15 |
| Day High | 27.03 |
| Day Low | 24.49 |
| 52-Week High | 32.27 |
| 52-Week Low | 13.37 |
| Volume | 679,673 |
| Average Volume | 361,098 |
| Market Cap | 852.99M |
| PE | -8.1 |
| EPS | -3.27 |
| Moving Average 50 Days | 21.13 |
| Moving Average 200 Days | 21.07 |
| Change | 1.84 |
If you invested $1000 in Dianthus Therapeutics, Inc. (DNTH) since IPO date, it would be worth $114.07 as of September 07, 2025 at a share price of $26.5. Whereas If you bought $1000 worth of Dianthus Therapeutics, Inc. (DNTH) shares 5 years ago, it would be worth $235.93 as of September 07, 2025 at a share price of $26.5.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 29, 2025 11:00 AM GMT
NEW YORK and WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmu
Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors
GlobeNewswire Inc.
May 22, 2025 8:10 PM GMT
Dr. Read brings >30 years of leadership and scientific expertise in the biopharmaceutical industry Previously served as CEO and Founder of Mariana Oncology until its acquisition by Novartis in 2024 and CSO of Ra Pharma until its acquisition by UCB in
Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September
GlobeNewswire Inc.
May 05, 2025 11:00 AM GMT
MaGic trial exceeded enrollment target of 60 patients Top-line results anticipated this September will be the first of three DNTH103 catalysts by YE'26 Building a neuromuscular franchise with DNTH103 in gMG, CIDP and MMN with a potential best-in-clas